Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano, Radu Bogdan Mateescu, Kang Moon Lee, Chang Soo Eun, Sang Joon Lee, Sung Young Lee, Ho Ung Kim, Stefan Schreiber, Heather Fowler, Raymond Cheung, Young Ho Kim^*

^*Corresponding author for this work

Internal Medicine

University of Ulsan
Krasnoyarsk Regional Clinical Hospital
Nizhny Novgorod Regional Clinical Hospital N A Semashko
Novosibirsk State Medical University
Sheba Medical Center at Tel Hashomer
Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv
Tel Aviv Sourasky Medical Center
Odesa Reg Clin Hosp
Yonsei University
San Camillo Hospital
Colentina Hospital
Carol Davila University of Medicine and Pharmacy
The Catholic University of Korea
Hanyang University
Celltrion
Kiel University
Pfizer
Sungkyunkwan University

Research output: Contribution to journal › Article › peer-review

172 Scopus citations

Sort by
Weight
Alphabetically

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Fingerprint

Keyphrases

Medicine and Dentistry

Immunology and Microbiology